AVA-291 Female Testosterone Shows 1,000-Fold Lower Breast Cell Proliferation at AACR 2026
There is not a single FDA-approved testosterone product designed for women. As of 2026, women seeking testosterone therapy receive repurposed male formulations at fractional doses, guided by practitioner experience rather than evidence-based dosing standards. The clinical rationale has long been established. The regulatory infrastructure has not.
That gap is now beginning to close. Aviva Bio is presenting data at the AACR Annual Meeting in April 2026 showing that AVA-291, its deuterium-modified testosterone compound, stimulates breast cancer cell proliferation approximately 1,000-fold less than standard testosterone. The FDA has already provided formal development pathway guidance through a Type B meeting in January 2026.
Testosterone Is Not Optional for Women’s Health
Testosterone is present in women at higher circulating concentrations than estrogen throughout the reproductive years. The ovaries and adrenal glands produce it continuously. What changes across perimenopause and menopause is not just estrogen, but the broader hormonal environment, including a measurable decline in testosterone.
The consequences are not limited to sexual desire. Testosterone influences muscle protein synthesis, bone density maintenance, cognitive clarity, energy metabolism, and mood regulation. The overlap between perimenopausal symptoms and the effects of testosterone decline, fatigue, reduced libido, decreased muscle tone, difficulty concentrating, is substantial and clinically underappreciated.
The Menopause Society confirmed in 2023 that the evidence base for testosterone use in women with HSDD (hypoactive sexual desire disorder) is consistent and well-supported, including for perimenopausal women before menstruation has fully ceased. Evidence also extends to late reproductive-age women and those with premature or early menopause.
Why There Are Zero Approved Products
The absence of an approved female testosterone product is not a scientific gap. It is a regulatory and commercial one.
The primary barrier has been breast safety. Testosterone undergoes aromatization, an enzymatic conversion via the enzyme aromatase, into estradiol. This conversion happens systemically and locally within breast tissue. Estrogen produced locally in breast cells can stimulate tumor cell proliferation, which is why the FDA identified this conversion as a central risk requiring specific characterization before approving any female testosterone therapy.
Without a clear regulatory pathway, pharmaceutical companies had little incentive to invest in female-specific testosterone development. The result: decades of off-label use where practitioners prescribe 0.5 to 2 percent male-formulated transdermal testosterone cream at approximately 1/10 to 1/20 the standard male dose, with no standardized dosing guidance.
Menopause Society and International Menopause Society both support testosterone therapy for HSDD, yet the regulatory architecture for a dedicated female product has been absent until now.
What Deuterium Substitution Does
AVA-291 is classified as d3-testosterone, a deuterium-substituted isotopologue of testosterone. The structural change is minimal but mechanically significant: select hydrogen atoms at specific positions on the testosterone molecule are replaced with deuterium, the naturally occurring heavy isotope of hydrogen found in ordinary water.
The result exploits a fundamental principle of chemistry called the kinetic isotope effect. The carbon-deuterium bond is stronger than the carbon-hydrogen bond. Breaking it requires more energy. Aromatase, the enzyme responsible for converting testosterone to estradiol, cannot cleave the C-D bond efficiently. The conversion to estrogen in breast tissue is therefore substantially slowed.
Critically, androgen receptor binding is preserved. The molecular geometry of AVA-291 is essentially identical to standard testosterone, so the receptor recognizes it normally. The intended pharmacological effects of testosterone, on bone, muscle, mood, cognition, and sexual desire, remain active. The aromatization pathway in breast tissue is selectively impaired.
This is not a partial improvement. It is a structural redesign of the molecule’s metabolic profile.
What the 1,000-Fold Difference Means
The AACR 2026 data include MCF-7 breast cancer cell line experiments, a standard model for evaluating estrogen-driven breast tumor growth. AVA-291 demonstrated approximately 1,000-fold lower potential to stimulate breast cancer cell proliferation compared to standard testosterone.
In the context of female testosterone development, this number addresses the specific concern the FDA cited as the critical safety barrier. The aromatization-to-local-estrogen pathway is the mechanism of concern. AVA-291 disrupts that pathway at the molecular level.
The FDA’s Type B meeting guidance in January 2026 indicates the agency is willing to evaluate AVA-291 through a development pathway that accounts for this differentiated safety profile. Barbara Levy, MD, Chief Medical Officer at Visana Health and a member of Aviva Bio’s Scientific Advisory Board, described this as a pivotal moment in addressing a significant unmet need in women’s hormone therapy.
Options Available Now for HSDD
For women currently experiencing perimenopausal or postmenopausal HSDD, the options are narrow.
FDA-approved treatments for HSDD are flibanserin (Addyi) and bremelanotide (Vyleesi). Both were approved for premenopausal women and are not testosterone-based. Neither addresses the hormonal context of perimenopause directly.
Prasterone (Intrarosa), an intravaginal DHEA product, is FDA-approved for dyspareunia from vaginal atrophy, not for HSDD as a primary indication. DHEA converts peripherally to testosterone and estrogen, but with a different pharmacokinetic profile than direct testosterone therapy.
Off-label transdermal testosterone remains the most commonly used approach for peri- and postmenopausal HSDD. Practitioners typically use male-formulated 1 to 2 percent testosterone cream at fractional doses. The absence of standardized female dosing means individual outcomes vary considerably.
AVA-291’s Phase 1 trial, planned for 2026, will characterize safety and pharmacokinetics. The path from Phase 1 to FDA approval typically spans five or more years. The significance of the current moment is not an imminent treatment option. It is that the FDA has opened a defined development pathway that did not exist before, and that the compound entering that pathway has addressed the central mechanistic concern from the outset.
Q. When will AVA-291 be available for prescription?
Aviva Bio is targeting Phase 1 clinical trial initiation in early 2026. FDA approval typically requires several years of clinical development after that. If you are currently experiencing perimenopausal HSDD, speak with your physician about off-label transdermal testosterone options available now.
Q. Is deuterium substitution safe? Is it radioactive?
Deuterium is a stable, naturally occurring isotope of hydrogen found in ordinary water (HDO). It is not radioactive and has no known toxicity. In AVA-291, select hydrogen atoms in the testosterone molecule are replaced with deuterium, slowing the enzymatic conversion to estrogen while preserving androgen receptor activity.
Q. What options exist right now for women with low testosterone or HSDD?
No FDA-approved testosterone therapy for women currently exists. Off-label use of male-formulated transdermal testosterone at 1/10 to 1/20 the standard male dose is practiced by some clinicians. FDA-approved options for HSDD are flibanserin (Addyi) and bremelanotide (Vyleesi), both indicated for premenopausal women and not testosterone-based. DHEA (prasterone/Intrarosa) is approved for vaginal atrophy, not libido.